查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2102949

全球中風市場－策略分析與預測（2026-2035）

Global Stroke Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 158 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球中風市場預計將從 2026 年的 472 億美元成長到 2035 年的 899 億美元，複合年成長率為 7.4%。

隨著綜合卒中中心的建立、對人工智慧（AI）診斷成像和下一代溶栓療法的投資增加，卒中治療和管理正在發生變革，為製藥、生物技術和醫療設備行業創造了巨大的商機。

中風仍然是一項重大的公共衛生挑戰，也是全球主要的死亡和長期殘疾原因之一。此疾病包括缺血性中風、出血性中風和短暫性腦缺血發作（TIA），其中缺血性中風佔絕大多數。快速診斷和及時介入對於改善患者預後至關重要，這也推動了對創新療法、血管內治療和綜合中風護理網路的持續投入。

市場促進因素

全球中風負擔日益加重

人口老化和心血管疾病風險因素的增加導致中風發生率不斷上升，進而擴大了對急性期照護、二級預防和長期復健服務的需求。高血壓、糖尿病、肥胖、血脂異常症、吸菸和心房顫動仍然是全球中風發生率上升的主要因素。

機械取栓術的推廣

機械取栓術已成為合格的大血管閉塞性缺血性中風患者的標準治療方法。隨著綜合中風中心的擴建和醫生技術水平的提高，血管內治療的日益普及持續推動著市場成長。

擴大下一代溶栓藥物的應用

由於替奈普酶等簡化溶栓療法給藥方便、效率高，臨床指引擴大推薦此類療法。監管機構的持續支持和醫生對其日益成長的接受度，正在推動對創新溶栓藥物的需求。

擴大中風醫療基礎設施

世界各地的醫療保健系統都在投資建造綜合中風中心、中風緊急應變網路、遠距中風計畫和快速診斷能力，以減少治療延誤並改善臨床結果。

市場限制因素

治療時間的限制

由於溶栓治療的效果在疾病發作後迅速下降，因此能夠接受急性介入治療的患者比例有限。

顱內出血風險

由於仍有嚴重出血併發症的風險，溶栓療法的廣泛應用受到限制，因此必須謹慎選擇患者。

先進的中風治療中心資源有限。

在許多發展中地區，仍然缺乏專門的中風中心、介入神經放射學專家和先進的影像基礎設施，限制了患者獲得最佳中風治療的機會。

目錄

第1章執行摘要

  • 市場概覽
  • 主要發現
  • 中風市場概覽
  • 流行病學方面的主要發現
  • 主要非處方治療藥物概述
  • 管道開發亮點
  • 市場規模及預測概要
  • 主要成長機遇
  • 策略建議

第2章 疾病與流行病學分析

  • 中風概述
    • 定義和臨床概述
    • 疾病負擔及其對公共衛生的影響
    • 中風的分類
  • 中風的病理生理學
    • 缺血性中風
    • 出血性中風
    • 短暫性腦缺血發作（TIA）
  • 風險因子和疾病病因
    • 高血壓
    • 心房顫動
    • 糖尿病
    • 血脂異常症
    • 肥胖
    • 吸煙和飲酒
    • 高齡化社會
  • 流行病學分析
    • 全球盛行率
    • 全球發病率
    • 死亡率分析
    • 殘障負擔分析
    • 復發性卒中患者群體
  • 按類型分類的中風流行病學
    • 缺血性中風
    • 腦出血
    • 蜘蛛網膜下腔出血
    • 短暫性腦缺血發作（TIA）
  • 基於人口統計學的流行病學
    • 基於年齡的分析
    • 基於性別的趨勢
    • 高風險族群分析
  • 流行病學預測

第3章 市場動態

  • 市場促進因素
    • 全球中風負擔日益加重
    • 人口老化
    • 提高意識和早期診斷
    • 擴大急性中風護理服務的覆蓋範圍
    • 再灌注治療的進展
    • 擴大二級預防
  • 市場限制因素
    • 治療窗口期較窄
    • 與獲得治療相關的挑戰
    • 醫療保健成本不斷上漲
    • 神經保護治療方案有限
  • 市場機遇
    • 神經保護藥物的研發
    • 再生醫學方法
    • 人工智慧驅動的中風管理
    • 進入新興市場
  • 市場挑戰
    • 患者就醫延誤
    • 中風後殘疾的負擔
    • 還款限制
    • 臨床試驗的複雜性
  • 波特五力分析
  • PESTLE分析
  • 價值鏈分析
  • 未滿足需求的評估

第4章 商業和市場進入

  • 市場進入概覽
  • 還款狀態
  • 醫療科技評估趨勢
  • 定價分析
  • 病人准入計劃
  • 支付方的觀點
  • 市場准入面臨的挑戰
  • 市場進入機會

第5章：創新與通路的現狀

  • 管道概覽
  • 管線分析：依開發階段分類
    • 藥物發現與臨床前研究
    • 第一階段
    • 第二階段
    • 第三階段
  • 管道分析：按模式
    • 低分子化合物
    • 生物製劑
    • 細胞療法
    • 基因治療
    • 聯合治療
  • 管道分析：按作用機制分析
    • 神經保護
    • 溶栓促進
    • 抗發炎機制
    • 神經再生
    • 基於幹細胞的方法
  • 臨床試驗現狀
    • 正在進行的 I 期臨床試驗
    • 正在進行的二期臨床試驗
    • 正在進行的III期臨床試驗
    • 按地區分類的臨床試驗分佈
    • 按申辦方類型分類的臨床試驗分佈
  • 新興技術
    • 基於生物標記的患者選擇
    • 人工智慧驅動的中風管理
    • 數位療法
    • 精準醫療方法
  • 許可、合作研究和夥伴關係活動
  • 併購分析

第6章 當前治療狀況

  • 目前治療框架
  • 急性中風的治療
    • 靜脈溶栓治療
    • 機械血栓切除術
    • 神經重症監護
  • 次發性預防中風
    • 抗血小板治療
    • 抗凝血治療
    • 降血脂治療
    • 血壓管理
  • 非處方藥的現狀
    • Alteplase（Activase）
    • 特內克特·普拉澤
    • 阿斯匹靈
    • Clopidogrel
    • 奇卡格雷羅（Brilinta）
    • Rivaroxaban（Zarelto）
    • Apixaban（艾樂妥）
    • Dabigatran（Pradaxa）
    • 艾多沙班（Lykiana/Saveisa）
  • 中風復健現狀
    • 物理復健
    • 職業療法
    • 語言治療
    • 數位復健解決方案
  • 按類型分類的中風治療流程

第7章 全球中風市場預測報告：市場規模與預測

  • 全球市場概覽
  • 過往市場分析
  • 預測的前提條件
  • 全球市場預測
  • 市場預測：按治療類型分類
  • 市場預測：按指標
  • 市場預測：依給藥途徑分類
  • 市場預測：依最終用戶分類
  • 機會評估

第8章：全球中風市場預測報告的細分

  • 按筆畫類型
    • 缺血性中風
      • 血栓性
      • 栓塞
    • 出血性中風
    • 短暫性腦缺血發作（TIA）
    • 其他
  • 依藥物類型
    • 溶栓藥物
    • 抗血小板藥物
    • 抗凝血物
    • 其他
  • 按治療類型
    • 靜脈注射藥物
    • 血管內治療
    • 手術治療
      • 機械血栓切除術
      • 頸動脈切除術（CEA）
      • 其他
  • 基於嚴重程度
    • 溫和的
    • 緩和
    • 嚴重
  • 按年齡層
    • 20歲以下
    • 20-50歲
    • 50至70歲
    • 70歲以上
  • 最終用戶
    • 醫院
    • 專科診所
    • 復健中心
    • 其他

第9章 區域分析（區域層級）

  • 北美洲
    • 市場規模及預測
    • 需求要素
    • 區域法規概述
    • 競爭強度
  • 歐洲
    • 市場規模及預測
    • 需求要素
    • 區域法規概述
    • 競爭強度
  • 亞太地區
    • 市場規模及預測
    • 需求促進因素
    • 區域法規概述
    • 競爭強度
  • 拉丁美洲
    • 市場規模及預測
    • 需求促進因素
    • 區域法規概述
    • 競爭強度
  • 中東和非洲
    • 市場規模及預測
    • 需求促進因素
    • 區域法規概述
    • 競爭強度

第10章 主要國家分析

  • 加拿大
  • 德國
  • 中國
  • 日本
  • 印度

第11章 法規與政策概述

  • 全球法規概述
  • 美國FDA框架
    • 藥物核准流程
    • 快速審查程序
  • 歐洲藥品管理局（EMA）
    • 集中核准流程
    • 市場進入考量
  • 日本的PMDA框架
  • 印度的CDSCO框架
  • 中國國家藥品監督管理局 (NMPA) 框架
  • 孤兒藥和特殊認定項目
  • 藥物安全監測要求
  • 影響中風藥物的監管趨勢

第12章 競爭格局

  • 市佔率分析
  • 競爭基準
  • 產品系列評估
  • 管道競爭性評估
  • 策略舉措
    • 合夥
    • 授權協議
    • 獲得
    • 區域擴大策略
  • SWOT分析
  • 競爭定位矩陣

第13章：公司簡介

  • Genentech
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Bayer AG
  • Johnson & Johnson
  • Daiichi Sankyo
  • Sanofi
  • Novo Nordisk
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • AbbVie Inc.

第14章：未來展望

  • 2035 年之前的市場趨勢
  • 一種新的治療模式
  • 未來商機
  • 管道推出影響評估
  • 精準醫療的前景
  • 人工智慧與數位健康的融合
  • 分析師建議

第15章：調查方法

  • 調查範圍和目標
  • 市場的定義
  • 資料收集和調查方法
    • 初步調查
    • 第二次調查
  • 市場規模估算調查方法
    • 自上而下的方法
    • 自下而上的方法
    • 數據三角測量
  • 預測調查方法
  • 流行病學建模框架
  • 管道評估框架
  • 競爭資訊分析框架
  • 先決條件和限制
  • 簡稱和定義
簡介目錄
Product Code: KSI-008719

The Global Stroke Market is expected to grow at a CAGR of 7.4% from a market value of USD 47.2 billion in 2026 to USD 89.9 billion in 2035.

Growing investments in comprehensive stroke centers, artificial intelligence-assisted imaging, and next-generation thrombolytic therapies are transforming stroke management while creating significant commercial opportunities across pharmaceutical, biotechnology, and medical device industries.

Stroke is one of the leading causes of death and long-term disability worldwide and remains a major public health challenge. The disease includes ischemic stroke, hemorrhagic stroke, and transient ischemic attack (TIA), with ischemic stroke accounting for the majority of cases. Rapid diagnosis and timely intervention remain essential for improving patient outcomes, driving continued investment in innovative therapeutics, endovascular procedures, and integrated stroke care networks.

Market Drivers

Rising Global Stroke Burden

The growing incidence of stroke associated with aging populations and increasing cardiovascular risk factors continues to expand demand for acute treatment, secondary prevention, and long-term rehabilitation services. Hypertension, diabetes, obesity, dyslipidemia, smoking, and atrial fibrillation remain the primary contributors to rising stroke incidence worldwide.

Expansion of Mechanical Thrombectomy

Mechanical thrombectomy has become a standard treatment for eligible patients with large-vessel occlusion ischemic stroke. Increasing adoption of endovascular therapy, supported by expanding comprehensive stroke centers and improved physician expertise, continues to drive market growth.

Growing Adoption of Next-Generation Thrombolytics

Clinical guidelines increasingly support simplified thrombolytic therapies such as tenecteplase because of their ease of administration and favorable workflow efficiency. Continued regulatory support and physician adoption are strengthening demand for innovative thrombolytic agents.

Expansion of Stroke Care Infrastructure

Healthcare systems worldwide are investing in comprehensive stroke centers, emergency stroke networks, tele-stroke programs, and rapid diagnostic capabilities to reduce treatment delays and improve clinical outcomes.

Market Restraints

Limited Treatment Window

The effectiveness of thrombolytic therapy declines rapidly after symptom onset, limiting the proportion of patients eligible for acute intervention.

Risk of Intracranial Hemorrhage

The potential for serious bleeding complications continues to limit broader utilization of thrombolytic therapies and requires careful patient selection.

Limited Access to Advanced Stroke Centers

Many developing regions continue to experience shortages of specialized stroke centers, neurointerventional specialists, and advanced imaging infrastructure, restricting access to optimal stroke care.

Market and Technology Insights

The global stroke market can be segmented by drug type, indication, treatment type, end user, and geography.

By drug type, the market includes thrombolytics, antiplatelet agents, anticoagulants, and other supportive therapies. Thrombolytics remain central to acute ischemic stroke treatment, while antiplatelet and anticoagulant therapies play a critical role in long-term secondary prevention.

By indication, the market comprises ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and other cerebrovascular disorders. Ischemic stroke accounts for the largest market share because it represents the majority of stroke cases and has well-established pharmacological and interventional treatment options.

By treatment type, the market includes intravenous medication, endovascular therapy, surgical procedures including mechanical thrombectomy and carotid endarterectomy, and rehabilitation services. Endovascular therapy continues to experience rapid growth because of expanding evidence supporting improved functional outcomes in eligible patients.

By end user, the market covers hospitals, specialty stroke centers, rehabilitation centers, and other healthcare facilities. Comprehensive stroke centers remain the primary providers of advanced stroke diagnosis and treatment.

Technological innovations including artificial intelligence-assisted imaging, automated stroke triage, tele-stroke networks, advanced neuroimaging, digital health platforms, and robotic-assisted neurointerventional procedures are improving diagnostic accuracy, reducing treatment delays, and enhancing patient outcomes.

Market Trends

The global stroke market continues to evolve through advances in acute intervention and precision stroke care.

Key market trends include:

  • Increasing adoption of mechanical thrombectomy.
  • Expansion of tenecteplase and next-generation thrombolytic therapies.
  • Growing implementation of AI-assisted stroke imaging.
  • Expansion of comprehensive stroke centers.
  • Greater emphasis on rapid diagnosis and treatment pathways.
  • Increasing investment in neuroprotective therapies.
  • Strengthening secondary prevention through personalized cardiovascular risk management.

Regional Insights

North America remains the largest stroke market because of advanced healthcare infrastructure, comprehensive stroke networks, favorable reimbursement systems, and strong adoption of innovative therapeutics and interventional procedures. The region also leads global clinical research and commercialization activities.

Europe continues to maintain a significant market share through established stroke treatment pathways, structured reimbursement systems, and widespread implementation of evidence-based clinical guidelines.

Asia-Pacific is expected to witness the fastest market growth owing to rapid population aging, increasing stroke incidence, expanding healthcare infrastructure, improving emergency stroke care, and growing healthcare investment across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually strengthening stroke care through healthcare modernization, improved referral systems, and increasing investment in specialized stroke treatment facilities.

Competitive Landscape

The global stroke market includes multinational pharmaceutical companies, biotechnology firms, medical device manufacturers, diagnostic imaging companies, and digital health providers.

Market participants continue investing in next-generation thrombolytics, neuroprotective therapies, artificial intelligence-enabled imaging, mechanical thrombectomy technologies, precision medicine, and integrated stroke care platforms. Strategic collaborations, licensing agreements, mergers and acquisitions, and geographic expansion remain key competitive strategies supporting long-term market growth.

Future Outlook

The future of the stroke market is expected to be driven by continued advances in acute stroke treatment, artificial intelligence, neuroprotection, precision medicine, and digital healthcare. Broader implementation of comprehensive stroke systems of care, AI-assisted imaging, wearable monitoring technologies, and personalized secondary prevention strategies is expected to improve patient outcomes while expanding commercial opportunities.

Continued research into neuroprotective agents, regenerative medicine, and advanced endovascular technologies is expected to further transform stroke management throughout the forecast period.

Conclusion

The global Stroke Market is expected to experience sustained growth through 2035, supported by increasing stroke incidence, expanding adoption of advanced reperfusion therapies, growing investment in stroke care infrastructure, and continuous innovation in pharmaceuticals and medical technologies. Although challenges related to treatment timing, access to specialized care, and safety considerations remain, ongoing advances in artificial intelligence, neurointervention, and precision medicine are expected to improve patient outcomes and create significant opportunities for healthcare providers, pharmaceutical companies, medical device manufacturers, and investors.

Key Benefits of this Report

  • Comprehensive analysis of the global stroke market and future growth opportunities.
  • Detailed evaluation of market drivers, restraints, treatment innovations, and technology trends.
  • Competitive assessment of leading companies, strategic developments, and commercialization activities.
  • Insights into regional market dynamics, regulatory developments, and future investment opportunities.
  • Valuable resource for pharmaceutical companies, biotechnology firms, medical device manufacturers, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Market forecasting, competitive intelligence, portfolio optimization, investment analysis, licensing and partnership evaluation, commercialization planning, regulatory strategy development, market entry assessment, and identification of emerging business opportunities.

Report Coverage

  • Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
  • Comprehensive analysis of the global stroke market by drug type, indication, treatment type, end user, and geography
  • Evaluation of market size, growth drivers, restraints, competitive landscape, and emerging treatment trends
  • Assessment of regulatory frameworks, reimbursement landscape, strategic collaborations, licensing activities, mergers and acquisitions, and commercialization strategies
  • Analysis of thrombolytics, antiplatelet agents, anticoagulants, endovascular therapies, artificial intelligence-enabled diagnostics, neuroprotective therapies, and future market opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Overview
  • 1.2 Key Findings
  • 1.3 Stroke Market Snapshot
  • 1.4 Key Epidemiology Insights
  • 1.5 Key Commercialized Therapies Overview
  • 1.6 Pipeline Development Highlights
  • 1.7 Market Size and Forecast Summary (2025-2035)
  • 1.8 Key Growth Opportunities
  • 1.9 Strategic Recommendations

2. Disease & Epidemiology Analysis

  • 2.1 Introduction to Stroke
    • 2.1.1 Definition and Clinical Overview
    • 2.1.2 Disease Burden and Public Health Impact
    • 2.1.3 Stroke Classification
  • 2.2 Stroke Pathophysiology
    • 2.2.1 Ischemic Stroke
    • 2.2.2 Hemorrhagic Stroke
    • 2.2.3 Transient Ischemic Attack (TIA)
  • 2.3 Risk Factors and Disease Etiology
    • 2.3.1 Hypertension
    • 2.3.2 Atrial Fibrillation
    • 2.3.3 Diabetes Mellitus
    • 2.3.4 Dyslipidemia
    • 2.3.5 Obesity
    • 2.3.6 Smoking and Alcohol Consumption
    • 2.3.7 Aging Population
  • 2.4 Epidemiology Analysis
    • 2.4.1 Global Prevalence
    • 2.4.2 Global Incidence
    • 2.4.3 Mortality Analysis
    • 2.4.4 Disability Burden Analysis
    • 2.4.5 Recurrent Stroke Population
  • 2.5 Epidemiology by Stroke Type
    • 2.5.1 Ischemic Stroke
    • 2.5.2 Intracerebral Hemorrhage
    • 2.5.3 Subarachnoid Hemorrhage
    • 2.5.4 Transient Ischemic Attack
  • 2.6 Epidemiology by Demographics
    • 2.6.1 Age-Based Analysis
    • 2.6.2 Gender-Based Analysis
    • 2.6.3 High-Risk Population Analysis
  • 2.7 Epidemiology Forecast (2025-2035)

3. Market Dynamics

  • 3.1 Market Drivers
    • 3.1.1 Rising Global Stroke Burden
    • 3.1.2 Growing Aging Population
    • 3.1.3 Increasing Awareness and Early Diagnosis
    • 3.1.4 Expanding Access to Acute Stroke Care
    • 3.1.5 Advancements in Reperfusion Therapies
    • 3.1.6 Increasing Secondary Prevention Adoption
  • 3.2 Market Restraints
    • 3.2.1 Narrow Therapeutic Time Windows
    • 3.2.2 Treatment Accessibility Challenges
    • 3.2.3 High Healthcare Costs
    • 3.2.4 Limited Neuroprotective Treatment Options
  • 3.3 Market Opportunities
    • 3.3.1 Neuroprotective Drug Development
    • 3.3.2 Regenerative Medicine Approaches
    • 3.3.3 AI-Enabled Stroke Management
    • 3.3.4 Emerging Market Expansion
  • 3.4 Market Challenges
    • 3.4.1 Delayed Patient Presentation
    • 3.4.2 Post-Stroke Disability Burden
    • 3.4.3 Reimbursement Constraints
    • 3.4.4 Clinical Trial Complexity
  • 3.5 Porter's Five Forces Analysis
  • 3.6 PESTLE Analysis
  • 3.7 Value Chain Analysis
  • 3.8 Unmet Needs Assessment

4. Commercial & Market Access

  • 4.1 Market Access Overview
  • 4.2 Reimbursement Landscape
  • 4.3 Health Technology Assessment Trends
  • 4.4 Pricing Analysis
  • 4.5 Patient Access Programs
  • 4.6 Payer Perspectives
  • 4.7 Market Access Challenges
  • 4.8 Market Access Opportunities

5. Innovation & Pipeline Landscape

  • 5.1 Pipeline Overview
  • 5.2 Pipeline Analysis by Development Stage
    • 5.2.1 Discovery and Preclinical
    • 5.2.2 Phase I
    • 5.2.3 Phase II
    • 5.2.4 Phase III
  • 5.3 Pipeline Analysis by Modality
    • 5.3.1 Small Molecules
    • 5.3.2 Biologics
    • 5.3.3 Cell Therapies
    • 5.3.4 Gene Therapies
    • 5.3.5 Combination Therapies
  • 5.4 Pipeline Analysis by Mechanism of Action
    • 5.4.1 Neuroprotection
    • 5.4.2 Thrombolysis Enhancement
    • 5.4.3 Anti-Inflammatory Mechanisms
    • 5.4.4 Neuroregeneration
    • 5.4.5 Stem Cell-Based Approaches
  • 5.5 Clinical Trial Landscape
    • 5.5.1 Ongoing Phase I Trials
    • 5.5.2 Ongoing Phase II Trials
    • 5.5.3 Ongoing Phase III Trials
    • 5.5.4 Trial Distribution by Geography
    • 5.5.5 Trial Distribution by Sponsor Type
  • 5.6 Emerging Technologies
    • 5.6.1 Biomarker-Based Patient Selection
    • 5.6.2 AI-Driven Stroke Management
    • 5.6.3 Digital Therapeutics
    • 5.6.4 Precision Medicine Approaches
  • 5.7 Licensing, Collaboration, and Partnership Activity
  • 5.8 Mergers and Acquisitions Analysis

6. Treatment Landscape

  • 6.1 Current Treatment Paradigm
  • 6.2 Acute Stroke Management
    • 6.2.1 Intravenous Thrombolysis
    • 6.2.2 Mechanical Thrombectomy
    • 6.2.3 Neurocritical Care
  • 6.3 Secondary Stroke Prevention
    • 6.3.1 Antiplatelet Therapy
    • 6.3.2 Anticoagulant Therapy
    • 6.3.3 Lipid-Lowering Therapy
    • 6.3.4 Blood Pressure Management
  • 6.4 Commercialized Drug Landscape
    • 6.4.1 Alteplase (Activase)
    • 6.4.2 Tenecteplase
    • 6.4.3 Aspirin
    • 6.4.4 Clopidogrel
    • 6.4.5 Ticagrelor (Brilinta)
    • 6.4.6 Rivaroxaban (Xarelto)
    • 6.4.7 Apixaban (Eliquis)
    • 6.4.8 Dabigatran (Pradaxa)
    • 6.4.9 Edoxaban (Lixiana/Savaysa)
  • 6.5 Stroke Rehabilitation Landscape
    • 6.5.1 Physical Rehabilitation
    • 6.5.2 Occupational Therapy
    • 6.5.3 Speech Therapy
    • 6.5.4 Digital Rehabilitation Solutions
  • 6.6 Treatment Algorithm by Stroke Type

7. Global Stroke Market Forecast Report Size & Forecast (2025-2035)

  • 7.1 Global Market Overview
  • 7.2 Historical Market Analysis (2020-2024)
  • 7.3 Forecast Assumptions
  • 7.4 Global Market Forecast (2025-2035)
  • 7.5 Market Forecast by Treatment Type
  • 7.6 Market Forecast by Indication
  • 7.7 Market Forecast by Route of Administration
  • 7.8 Market Forecast by End User
  • 7.9 Opportunity Assessment

8. Global Stroke Market Forecast Report Segmentation

  • 8.1 By Stroke Type
    • 8.1.1 Ischemic Stroke
      • 8.1.1.1. Thrombotic
      • 8.1.1.2. Embolic
    • 8.1.2 Hemorrhagic Stroke
    • 8.1.3 Transient Ischemic Attack
    • 8.1.4 Others
  • 8.2 By Drug Type
    • 8.2.1 Thrombolytics
    • 8.2.2 Antiplatelets
    • 8.2.3 Anticoagulants
    • 8.2.4 Others
  • 8.3 By Treatment Type
    • 8.3.1 IV Medication
    • 8.3.2 Endovascular Therapy
    • 8.3.3 Surgical Procedures
      • 8.3.3.1 Mechanical Thrombectomy
      • 8.3.3.2 Carotid Endarterectomy (CEA)
      • 8.3.3.3 Others
  • 8.4 By Severity Type
    • 8.4.1 Mild
    • 8.4.2 Moderate
    • 8.4.3 Severe
  • 8.5 By Age-Group
    • 8.5.1 Below 20 Years
    • 8.5.2 20 to 50 Years
    • 8.5.3 50 to 70 Years
    • 8.5.4 Older than 70 Years
  • 8.6 By End User
    • 8.6.1 Hospitals
    • 8.6.2 Specialty Clinics
    • 8.6.3 Rehabilitation Centers
    • 8.6.4 Others

9. Geographical Analysis (Regional Level)

  • 9.1 North America
    • 9.1.1 Market Size and Forecast
    • 9.1.2 Demand Drivers
    • 9.1.3 Regional Regulatory Overview
    • 9.1.4 Competitive Intensity
  • 9.2 Europe
    • 9.2.1 Market Size and Forecast
    • 9.2.2 Demand Drivers
    • 9.2.3 Regional Regulatory Overview
    • 9.2.4 Competitive Intensity
  • 9.3 Asia-Pacific
    • 9.3.1 Market Size and Forecast
    • 9.3.2 Demand Drivers
    • 9.3.3 Regional Regulatory Overview
    • 9.3.4 Competitive Intensity
  • 9.4 Latin America
    • 9.4.1 Market Size and Forecast
    • 9.4.2 Demand Drivers
    • 9.4.3 Regional Regulatory Overview
    • 9.4.4 Competitive Intensity
  • 9.5 Middle East & Africa
    • 9.5.1 Market Size and Forecast
    • 9.5.2 Demand Drivers
    • 9.5.3 Regional Regulatory Overview
    • 9.5.4 Competitive Intensity

10. Key Countries Analysis

  • 10.1 United States
    • 10.1.1 Market Size
    • 10.1.2 Stroke Epidemiology
    • 10.1.3 Regulatory Framework
    • 10.1.4 Reimbursement Landscape
    • 10.1.5 Key Companies and Products Presence
  • 10.2 Canada
  • 10.3 Germany
  • 10.4 United Kingdom
  • 10.5 France
  • 10.6 Italy
  • 10.7 Spain
  • 10.8 China
  • 10.9 Japan
  • 10.10 India
  • 10.11 South Korea
  • 10.12 Australia
  • 10.13 Brazil
  • 10.14 Mexico
  • 10.15 Saudi Arabia
  • 10.16 South Africa

11. Regulatory & Policy Landscape

  • 11.1 Global Regulatory Overview
  • 11.2 United States FDA Framework
    • 11.2.1 Drug Approval Pathways
    • 11.2.2 Expedited Programs
  • 11.3 European Medicines Agency (EMA)
    • 11.3.1 Centralized Approval Process
    • 11.3.2 Market Access Considerations
  • 11.4 Japan PMDA Framework
  • 11.5 India CDSCO Framework
  • 11.6 China NMPA Framework
  • 11.7 Orphan and Special Designation Programs
  • 11.8 Pharmacovigilance Requirements
  • 11.9 Regulatory Trends Impacting Stroke Therapeutics

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Competitive Benchmarking
  • 12.3 Product Portfolio Assessment
  • 12.4 Pipeline Competitiveness Assessment
  • 12.5 Strategic Initiatives
    • 12.5.1 Collaborations
    • 12.5.2 Licensing Agreements
    • 12.5.3 Acquisitions
    • 12.5.4 Geographic Expansion Strategies
  • 12.6 SWOT Analysis
  • 12.7 Competitive Positioning Matrix

13. Company Profiles

  • 13.1 Genentech
    • 13.1.1 Company Overview
    • 13.1.2 Approved Stroke-Related Products
    • 13.1.3 Key Indications
    • 13.1.4 Pipeline and Clinical Development Activities
    • 13.1.5 Strategic Outlook
  • 13.2 Boehringer Ingelheim
    • 13.2.1 Company Overview
    • 13.2.2 Approved Stroke-Related Products
    • 13.2.3 Key Indications
    • 13.2.4 Verified Pipeline Programs
    • 13.2.5 Strategic Outlook
  • 13.3 F. Hoffmann-La Roche Ltd
    • 13.3.1 Company Overview
    • 13.3.2 Approved Products Relevant to Stroke Management
    • 13.3.3 Key Indications
    • 13.3.4 Pipeline Activities
    • 13.3.5 Strategic Outlook
  • 13.4 Novartis AG
    • 13.4.1 Company Overview
    • 13.4.2 Approved Products Relevant to Stroke Prevention
    • 13.4.3 Key Indications
    • 13.4.4 Pipeline Activities
    • 13.4.5 Strategic Outlook
  • 13.5 Bayer AG
    • 13.5.1 Company Overview
    • 13.5.2 Approved Stroke-Related Products
    • 13.5.3 Key Indications
    • 13.5.4 Pipeline Activities
    • 13.5.5 Strategic Outlook
  • 13.6 Johnson & Johnson
    • 13.6.1 Company Overview
    • 13.6.2 Approved Stroke-Related Products
    • 13.6.3 Key Indications
    • 13.6.4 Pipeline Activities
    • 13.6.5 Strategic Outlook
  • 13.7 Daiichi Sankyo
    • 13.7.1 Company Overview
    • 13.7.2 Approved Stroke-Related Products
    • 13.7.3 Key Indications
    • 13.7.4 Pipeline Activities
    • 13.7.5 Strategic Outlook
  • 13.8 Sanofi
    • 13.8.1 Company Overview
    • 13.8.2 Cardiovascular and Stroke Prevention Portfolio
    • 13.8.3 Key Indications
    • 13.8.4 Pipeline Activities
    • 13.8.5 Strategic Outlook
  • 13.9 Novo Nordisk
    • 13.9.1 Company Overview
    • 13.9.2 Cardiometabolic Portfolio Relevant to Stroke Risk Reduction
    • 13.9.3 Key Indications
    • 13.9.4 Pipeline Activities
    • 13.9.5 Strategic Outlook
  • 13.10 AstraZeneca PLC
    • 13.10.1 Company Overview
    • 13.10.2 Approved Stroke-Related Products
    • 13.10.3 Key Indications
    • 13.10.4 Pipeline Activities
    • 13.10.5 Strategic Outlook
  • 13.11 Merck & Co., Inc.
    • 13.11.1 Company Overview
    • 13.11.2 Cardiovascular Portfolio Assessment
    • 13.11.3 Key Indications
    • 13.11.4 Pipeline Activities
    • 13.11.5 Strategic Outlook
  • 13.12 GlaxoSmithKline plc
    • 13.12.1 Company Overview
    • 13.12.2 Cardiovascular Portfolio Assessment
    • 13.12.3 Key Indications
    • 13.12.4 Pipeline Activities
    • 13.12.5 Strategic Outlook
  • 13.13 Eli Lilly and Company
    • 13.13.1 Company Overview
    • 13.13.2 Cardiometabolic Portfolio Relevant to Stroke Risk Reduction
    • 13.13.3 Key Indications
    • 13.13.4 Pipeline Activities
    • 13.13.5 Strategic Outlook
  • 13.14 AbbVie Inc.
    • 13.14.1 Company Overview
    • 13.14.2 Neuroscience Portfolio Assessment
    • 13.14.3 Key Indications
    • 13.14.4 Pipeline Activities
    • 13.14.5 Strategic Outlook

14. Future Outlook

  • 14.1 Market Evolution Through 2035
  • 14.2 Emerging Treatment Paradigms
  • 14.3 Future Commercial Opportunities
  • 14.4 Pipeline Launch Impact Assessment
  • 14.5 Precision Medicine Outlook
  • 14.6 AI and Digital Health Integration
  • 14.7 Analyst Recommendations

15. Methodology

  • 15.1 Research Scope and Objectives
  • 15.2 Market Definition
  • 15.3 Data Collection Methodology
    • 15.3.1 Primary Research
    • 15.3.2 Secondary Research
  • 15.4 Market Estimation Methodology
    • 15.4.1 Top-Down Approach
    • 15.4.2 Bottom-Up Approach
    • 15.4.3 Data Triangulation
  • 15.5 Forecasting Methodology
  • 15.6 Epidemiology Modeling Framework
  • 15.7 Pipeline Assessment Framework
  • 15.8 Competitive Intelligence Framework
  • 15.9 Assumptions and Limitations
  • 15.10 Abbreviations and Definitions